Combination Cytokine Therapy

Cohen, Seth M.; Kaufman, Howard L.

doi:10.1007/978-1-59745-455-1_20

Cited by 2 publications

(2 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since IL-2 and IFNα signal through distinct pathways, their synergistic potential has been assayed extensively, though clinical trials have failed to show a survival benefit from combination therapy over monotherapy (Cohen and Kaufman, 2007). However, since we had found serum-persistent FcIL2 to be more potent than IL-2 in delaying tumor progression together with TA99 (Zhu et al, 2015), we hypothesized that this regimen’s ability to mediate innate and adaptive immunity-dependent tumor cytotoxicity could be well complemented by IFNα’s pleiotropic effects.…”

Section: Introductionmentioning

confidence: 99%

Temporally Programmed CD8α + DC Activation Enhances Combination Cancer Immunotherapy

et al. 2016

View full text Add to dashboard Cite

Summary Numerous synergistic cancer immunotherapy combinations have been identified, but the effects of relative dose timing are rarely considered. In established syngeneic mouse tumor models, we found that staggering IFNα administration after, rather than before or simultaneously with, serum-persistent IL-2 and tumor-specific antibody significantly increased long-term survival. Successful combination therapy required IFNα-induced activation of cross-presenting CD8α+ DCs following release of antigenic tumor debris by the IL-2-and-antibody-mediated immune response. Due to decreased phagocytic ability post-maturation, DCs activated too early captured less antigen and could not effectively prime CD8+ T cells. Temporally programming DC activation to occur after tumoricidal activity enhanced tumor control by multiple distinct combination immunotherapies, highlighting dose schedule as an underappreciated factor that can profoundly affect the success of multi-component immunotherapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Temporally Programmed CD8α + DC Activation Enhances Combination Cancer Immunotherapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This can be achieved, for example, through intra-tumor administration of ex vivo activated alloreactive cytotoxic-T-lymphocytes, use of oncolytic viruses or treatment with cytokine-based drugs (Cohen and Kaufman, 2007; Moschos et al, 2007). Early work in this area includes construction of mathematical models, which reproduce dynamics of cancer cells targeted by oncolytic viruses (Paiva et al, 2008) and analysis of properties of these models (Wodarz and Komarowa, 2009).…”

Section: Models Of Therapy Taking Into Account Dynamics Of Intracementioning

confidence: 99%

Mathematical modeling as a tool for planning anticancer therapy

Świerniak

Kimmel

Śmieja

2009

European Journal of Pharmacology

111

View full text Add to dashboard Cite

We review a large volume of literature concerning mathematical models of cancer therapy, oriented towards optimization of treatment protocols. The review, although partly idiosyncratic, covers such major areas of therapy optimization as phase-specific chemotherapy, antiangiogenic therapy and therapy under drug resistance. We start from early cell-cycle progression models, very simple but admitting explicit mathematical solutions, based on methods of control theory. We continue with more complex models involving evolution of drug resistance and pharmacokinetic and pharmacodynamic effects. Then, we consider two more recent areas: angiogenesis of tumors and molecular signaling within and among cells. We discuss biological background and mathematical techniques of this field, which has a large although only partly realized potential for contributing to cancer treatment.

show abstract

Combination Cytokine Therapy

Cited by 2 publications

References 133 publications

Temporally Programmed CD8α + DC Activation Enhances Combination Cancer Immunotherapy

Temporally Programmed CD8α + DC Activation Enhances Combination Cancer Immunotherapy

Mathematical modeling as a tool for planning anticancer therapy

Contact Info

Product

Resources

About